Tesamorelin

Tesamorelin is an FDA-approved 44-amino acid GHRH analogue with a hexenoyl moiety at the N-terminus designed to resist degradation by dipeptidylaminopeptidase 4 (DPP4), maintaining superior bioavailability over native GHRH. Licensed specifically for reducing excess visceral fat in HIV-infected patients with lipodystrophy, tesamorelin demonstrates dose-dependent increases in plasma GH and IGF-1 levels. Clinical research confirms its capacity to selectively reduce trunk fat and visceral adipose tissue while improving lipid profiles, with mechanisms including enhanced lipolysis and metabolic remodeling of central adipose depots.

10mg